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Neuroblastoma, the most common and deadly 
extracranial solid tumor of childhood, has long provided a 
challenge to both clinicians and basic scientists.  Despite 
its high prevalence among pediatric cancers and extensive 
efforts over the last several decades, there is still been only 
marginal improvement in overall survival and almost no 
improvement in survival for high-risk neuroblastoma[1].   
Numerous  risk  stratification  studies  have  shown  that 
amplification  of  the  MYCN oncogene is the clearest 
clinical indicator of poor prognosis.  
Despite the importance of MYCN amplification in 
neuroblastoma, little work has been done to examine the 
transcriptional regulation of the MYCN amplicon.  In 
addition to transcriptional regulation, a second primary 
means through which cells regulate levels of  Mycn  is 
at the level of protein stability.  Therefore, exploring 
methods enabling targeting of Mycn protein stability is a 
major focus of current therapeutic research (reviewed in 
[2]).  If significant transcriptional regulation of the MYCN 
amplicon in neuroblastoma could be characterized and 
exploited, these could result in novel strategies to target 
this deadly disease.  
What do we know about transcriptional regulation 
of MYCN in neuroblastoma?  In conjunction with binding 
partners including Max and Miz, Myc family transcription 
factors (including c-MYC, MYCN, and MYCL) bind to 
specific “E-box” elements to regulate gene expression.   
E-boxes are quite common in the genome and are present 
in the promoter regions of approximately 25% of known 
genes indicating complex and tissue specific regulation of 
Myc mediated transcription [3].  While many downstream 
transcriptional  targets  of  c-Myc  have  been  determined 
(including  the  B-MYB  gene)[4],  detailed  analysis  and 
confirmation  of  MYCN  regulated  genes  is  of  vital 
importance  to  our  understanding  of  MYCN  mediated 
oncogenesis. In this issue of Oncotarget, Gualdrini et 
al propose the B-MYB transcription factor as one such 
target, and provide preliminary evidence for a reciprocal 
regulation between the amplified MYCN and the B-MYB 
transcription factors [5].
Expression of the B-MYB transcription factor has 
been previously shown to be a poor prognostic indicator 
in neuroblastoma, independent of MYCN  amplification 
[6]. In this study, Gualdrini et al  show  an  intriguing 
correlation  between  expression  of  mRNA  for  MYCN 
and B-MYB in neuroblastoma patient samples amplified 
for  MYCN, extending this observation to the protein 
level in several MYCN  amplified  neuroblastoma  cell 
lines.  Importantly, the correlation between MYCN and 
B-MYB  does  not  hold  true  in  MYCN  non-amplified 
samples.   Additionally,  using  CHIP  in  established  cell 
lines, the authors provide preliminary evidence that Mycn 
protein can bind to and induce transcription of B-MYC, 
consistent  with  B-MYB  as  a  transcriptional  target  of 
MYCN.  Perhaps most importantly, the study shows that 
knockdown of B-MYB by shRNA blocks proliferation in 
neuroblastoma cell lines with amplified MYCN.  However, 
mechanistic details of this synthetic anti-proliferative 
effect between knockdown of B-MYB and amplification 
of MYCN remain to be determined.  Also importantly, the 
authors use a single shRNA against BMYB, and do not 
extend this observation to primary tumors, thus limiting 
the impact of this result.  Lastly, B-MYB was also shown 
to bind to the MYCN promoter in chromatin-IP assays 
of MYCN amplified neuroblastoma cells in culture, and 
induced a relatively modest transcriptional upregulation 
of a MYCN promoter element.
The authors use these exciting albeit preliminary 
results to propose a novel model for a reciprocal 
regulatory loop between these two transcription factors.   
If  significant  epigenetic  and  transcriptional  regulation 
of  amplified  MYCN (implied by these studies) can be 
validated in primary tumors, these studies would support 
BMYB as target for therapeutic intervention in MYCN 
amplified cancers.  However, given myriad difficulties 
currently in-place in targeting Mycn itself, the ability to Oncotarget 2010; 1: 235-236 236 www.impactjournals.com/oncotarget
target both BMYC and MYCN in neuroblastoma raises its 
own group of challenges. 
RefeRences
1.  Maris JM. Recent advances in neuroblastoma. N Engl J 
Med. 2010; 362: 2202-11
2.  Gustafson WC,  Weiss WA. Myc proteins as therapeutic 
targets. Oncogene. 2010; 29: 1249-59
3.  Farnham PJ. Insights from genomic profiling of transcription 
factors. Nat Rev Genet 2009. 10: 605-16
4.  Fernandez  PC,  Frank  SR,  Wang  L,  Schroeder  M,  Liu 
S, Greene J, Cocito A, Amati B. Genomic targets of the 
human c-Myc protein. Genes Dev. 2003; 17: 1115-29
5.  Gualdrini F, Corvetta D, Cantilena S, Chayka O, Tanno 
B, Raschellà G, Sala A. Addiction of MYCN amplified 
tumours  to  B-MYB  underscores  a  reciprocal  regulatory 
loop. Oncotarget 2010; 1: this issue
6.  Raschella G, Cesi V, Amendola R, Negroni  A, Tanno  B, 
Altavista  P, Tonini  GP, De Bernardi B, Calabretta B. 
Expression of B-myb in neuroblastoma tumors is a poor 
prognostic factor independent from MYCN amplification. 
Cancer Res, 1999; 59: 3365-8